2370 Medinet
- 46
- -1-2.13%
Medinet News
The TOPIX 250 index of the Tokyo Stock Exchange rose for the third consecutive day, with strong demand for major stocks.
TOPIX Growth Market Index 812.45 +26.10 / volumne 0.2 billion 38.78 million shares / trading value 128.1 billion yen. TOPIX Growth Market 250 Index 634.78 +22.75 / volume 0.1 billion 64.43 million shares / trading value 97.7 billion yen. Today's growth market, the TOPIX Growth Market Index rose for the 10th consecutive day, and the TOPIX Growth Market 250 Index rose for the 3rd consecutive day. The number of rising stocks was 464, falling stocks were 93, unchanged stocks were 30. The US stock market continued to rise on the 19th. The Dow Jones Industrial Average was up 236.77 points.
Volume change rate ranking (9am) - RepliCel, Fujifilm Pharmaceuticals, etc. ranked in.
In the volume change rate ranking, by comparing the volume of the last 5 days with the volume on the delivery day, market participants can understand the trend of the market's interest. Top volume change rate [as of August 19, 9:32am] (compared to the average volume of the last 5 days): stock code, stock name, volume, 5-day average volume, volume change rate, and stock price change rate. <2389> Digital HD, 377200, 107185.08, 241.5%, 0% <488>
MDNT - Recognition of non-operating income
On the 9th, Medinet <2370> announced the recording of non-operating income for the cumulative period of the third quarter of the fiscal year 2024 (October 1, 2023 to June 30, 2024). In the cumulative period of the second quarter (October 1, 2023 to March 31, 2024), the investment business association achieved good results, and a profit of 0.02 billion yen was recorded from the investment business association, and 0.14 billion yen is expected to be recorded during the third quarter accounting period (April 1, 2024 to June 30, 2024).
Medinet has started manufacturing a new specific cell processed product called "S-DSC(R)" for hair regeneration.
On the 8th, Medinet announced that it will begin manufacturing specific cell processed products used in the treatment of male and female hair loss using cultured autologous hair follicle dermal sheath cells (DSC) outsourcing. This treatment involves taking DSC cells from the scalp of the occipital area that has not experienced hair loss, amplifying these cells in vitro, and administering the resulting specific cell processed product (S-DSC(R)) to the hair loss area. In recent years, research for hair regeneration for the purpose of treating hair loss has been progressing, but it takes time for hair to grow.
Medinet-- 3Q also had double-digit revenue growth, and cell processing sales revenue is progressing smoothly.
Medinet <2370> announced its third quarter results for the fiscal year ending September 2024 (October 2023-June 2024) on the 9th. Revenue increased by 19.8% YoY to ¥0.589 billion, operating loss was ¥0.996 billion (compared to a loss of ¥1.046 billion in the same period last year), ordinary loss was ¥0.948 billion (compared to a loss of ¥1.043 billion in the same period last year), and net loss for the quarter was ¥0.951 billion (compared to a loss of ¥1.045 billion in the same period last year). Sales of the cell processing industry increased by 19.9% YoY to ¥0.589 billion, driven by the expansion of cell processing outsourcing.
MEDINET Co. Sees Sales Rise Amidst Losses
Emerging Market Stock Digest: Covered dropped sharply, NexTone hit the daily limit.
<5253> Cover 1527 fell sharply by -210. After the end of trading on the 8th, the performance of the 1st quarter of the 2025 fiscal year was announced, and selling pressure has become dominant. Revenue was ¥6.416 billion (an increase of 24.8% compared to the same period last year), and operating profit was ¥0.834 billion (a decrease of 6.8%). While the delivery/content sector is performing well, it seems that it did not meet investors' expectations. The company has made progress in improving the overall profitability of its business, but at the same time, it is concurrently expanding its content production capabilities and revenue department.
Medinet: Third quarter financial report for the September 2024 period (Japanese standard) (non-consolidated)
Hot stocks digest (morning session): Toshiba Electronic Devices & Storage Corporation, Institute for Immunology and Genetics, MDNT, etc.
H-One<5989> is showing buying interest at the limit up of 926 yen. The company announced its first quarter results the day before, with operating profit turning from a loss of 0.26 billion yen in the same period last year to a profit of 4.21 billion yen. The progress rate for the full-year plan of 11 billion yen remains at 38%, leading to a positive impact. The North American segment's sales grew, and revenue was pushed up by appropriate pricing and the depreciation of the yen. There was also a reduction in manufacturing costs such as labor expenses and a decrease in amortization burden, leading to increased earnings.
Volume change rate ranking (9 o'clock) - Arent, Takashima and others are ranked.
In the volume change rate ranking, you can understand the interest of market participants in the trend of the selection and other factors by comparing the average volume of the past five days with the volume on the day of delivery. In the top volume change rate [as of 9:33 am, August 9th] (compared with the average volume of the past five days), stock code stock name volume average volume of the past 5 days volume change rate stock price change rate <6855> electronic materials 857700 107,185.08 149.61 % -0.015.
MDNT has started manufacturing and outsourcing a new specific cell processing product ('S-DSC') related to rapid hair regeneration.
Announcing the start of manufacturing entrusted specific cell processed products utilizing the in-house hair follicle sheath cells for the treatment of male and female pattern hair loss, and it is considered as a good material. In recent years, research on hair regeneration for the purpose of treating hair loss has been advancing, and it has been shown that hair growth can be promoted by culturing hair follicle sheath (DSC) cells located under the dermal sheath papilla cells, which are considered essential for hair growth, and administering them to the scalp as "S-DSCs".
Stem Inc, MDNT and others [Emerging Markets Press Release]
Acquired and subordinated the stock of Swaying Wind, who operates the WOLVES animal hospital. Started manufacturing specific cell products ('S-DSC') for hair regeneration under contract with MDNT. Registered patents (China) for peptides related to the peripheral peptides of LedaSemchidot (HMGB1 fragment peptide) at Stemlim Regenerative Induction Medicine. Massive exercise of Fanpep's 11th subscription rights (with modification clause for exercise price) to issue 0.67 million 4,000 shares starting from the first day.
McDonald's, Isetan Mitsukoshi, Rakuten G, ENEOS HD (9th) (1379-5076)
*The calendar above is tentative and subject to change due to company circumstances. ---------------------------------------August 9 (Friday) <1379> Hokuto <1381> Access <1384> Hokuriyo <1414> Showbond <1417> Miraito One <1429> Japan Aqua <142A> Gingerbread <1431> Livework <14
Will the search for double-digit stocks continue with elimination method vigilance?
The new emerging market this week may continue to be in a tough situation. In the US market over the weekend, the major stock indexes fell sharply due to concerns about economic slowdown, after the market expected the July employment statistics to be lower than expected. The growth market 250 index fell to the level of the COVID-19 shock in March 2020 as of last weekend, so it is likely to further decline this week. Although the yield on 10-year bonds in the US dropped significantly to below 3.8% since December last year, the Australian small/mid cap stocks, which are composed of small and medium-sized companies, may continue to decline.
Emerging markets outlook: be cautious of a one-step decline in the Growth Market 250 index, will continue to search for double-digit stocks by elimination method.
In the current market situation, there is strong selling pressure to avoid risks, and the emerging markets saw a significant decline this week. The rise and fall rates during this period showed that while the Nikkei average fell by -4.67%, the growth market index fell significantly further by -9.62%, and the growth market 250 index fell by -10.36%. Looking back as far as the former Mothers Index, this marked the lowest decline rate since the week of January 1, 2022, of -10.61%. Similar to the primary market, the strong selling pressure to avoid risk is due to factors such as the rapid appreciation of the yen after the meeting of the central banks of Japan, the US and China, and growing concern about a recession in the US economy.
MDNT Research Memo (10): Under the corporate vision 'VISION2030', we are proceeding with the development of a new medium-term management plan.
Progress of business activities and global strategy. Under the new management plan and corporate vision VISION2030, which will be launched in April 2022, Mr. Kubushiro took over as the new CEO from founder Mr. Kimura. The company is proceeding with the consideration of a new medium-term management plan that takes into account new perspectives and issues. Medinet <2370> announced "VISION2030" which outlines the company's desired state in 2030, with backcasting (from future to present).
MDNT Research Memo (9): The development policy for the treatment of chronic heart failure will be determined by the end of September 2024 based on the results of Phase IIb.
In the regenerative medicine product business, we are promoting two themes in product development: 1) Practical use of regenerative medicine products for the treatment of chronic heart failure (joint research and development with Kyushu University), and 2) Cultured cartilage using autologous cells for knee cartilage injuries.
MDNT Research Memo (8): Aim to establish ambidextrous management early and achieve profitability in the cell processing industry by September 2025 (2).
Increase the cell types and items of specific cell products manufactured under contract by pharmaceutical companies, universities, medical institutions, research institutions, etc. engaged in regenerative and cell therapy.
MDNT Research Memo (7): Aim to establish ambidextrous management early and achieve profitability in the cell processing industry by September 2025. (1)
Progress and growth strategy of Medinet's (2370) business activities: 1. Progress of cell processing business and future efforts. The cell processing business achieved profitability for the first time in the fiscal year ending September 2019, but due to the COVID-19 pandemic, patients receiving immune cell therapy (especially inbound patients) continued to refrain from visiting. In the fiscal year ending September 2023, as economic activity becomes more vigorous with the transition to COVID-19 infection control level 5 and immune cell therapy patients gradually return, the number of immune cell processing contracts is also on a recovery trend. The specific cell processing manufacturing industry is affected by the COVID-19 situation.
MDNT Research Memo (6): With abundant cash and deposits, the supply system for growth investment is solid.
Looking at the financial situation at the end of the second quarter of the September 2024 term, the total assets amounted to 61 billion yen (an increase of 466 million yen compared to the previous quarter).
Analysis
Price Target
No Data
